Clinical Trial Update: Study to Evaluate the Efficiency of FOLFIRI as Seconde-line Chemotherapy in Neuroendocrine Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update evaluating the FOLFIRI chemotherapy regimen as second-line treatment for Neuroendocrine Carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Carcinoma

Drugs mentioned

• 5-Fluorouracil (5-FU)
• FOLFIRI regimen (irinotecan + leucovorin + 5-fluorouracil)
• Irinotecan (Irinotecan)
• Leucovorin (folinic acid)

Snippet

Sponsor: Peking University | Conditions: Neuroendocrine Carcinoma | Phase 2 | Status: UNKNOWN